Search

Venkitasamy Kesavan Phones & Addresses

  • Highland Park, NJ
  • Boxborough, MA
  • 64 Mill St, Woburn, MA 01801
  • Worcester, MA
  • Piscataway, NJ

Publications

Us Patents

Chemically Modified Oligonucleotides

View page
US Patent:
7582744, Sep 1, 2009
Filed:
Aug 10, 2005
Appl. No.:
11/200703
Inventors:
Muthiah Manoharan - Weston MA,
Venkitasamy Kesavan - Woburn MA,
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07H 21/04
A61K 31/70
US Classification:
536 245, 536 231, 514 44
Abstract:
This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.

Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds

View page
US Patent:
7612078, Nov 3, 2009
Filed:
Mar 8, 2005
Appl. No.:
11/075565
Inventors:
Dale S. Dhanoa - Wakefield MA,
Oren Becker - Mevaseret Zion,
Silvia Noiman - Herzliyya,
A. Sekar Reddy - Burlington MA,
Srinivasa R. Cheruku - Lexington MA,
Rosa E. Melendez - Woburn MA,
Anurag Sharadendu - Bedford MA,
Dongli Chen - Brighton MA,
Yael Marantz - Kadima,
Sharon Shacham - Newton MA,
Alexander Heifetz - Bnei-Brak,
Boaz Inbal - Kfar Shmuel,
Venkitasamy Kesavan - Woburn MA,
Shay Bar-Haim - Netanya,
Assignee:
Epix Delaware, Inc. - Lexington MA
International Classification:
C07D 495/04
A61K 31/519
A61P 25/06
A61P 9/12
US Classification:
5142601, 544278
Abstract:
The invention relates to 5-HT receptor modulators, particularly 5-HTantagonists. Novel piperidinylamino-thieno[2,3-d]pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.

Single-Stranded And Double-Stranded Oligonucleotides Comprising A 2-Arylpropyl Moiety

View page
US Patent:
7626014, Dec 1, 2009
Filed:
Apr 27, 2005
Appl. No.:
11/115989
Inventors:
Muthiah Manoharan - Weston MA,
Venkitasamy Kesavan - Woburn MA,
Assignee:
Alnylam Pharmaceuticals - Cambridge MA
International Classification:
C07H 21/04
A61K 31/70
US Classification:
536 245, 536 231, 514 44
Abstract:
The present invention provides single-stranded and double-stranded oligonucleotides comprising at least one aralkyl ligand that improves the pharmacokinetic properties of the oligonucleotides. The aralkyl ligands of the present invention include naproxen, ibuprofen and derivatives thereof. The present invention also provides methods for modulating gene expression using the modified oligonucleotide compounds and compositions comprising those modified oligonucleotides.

Modified Irna Agents

View page
US Patent:
7745608, Jun 29, 2010
Filed:
Aug 10, 2004
Appl. No.:
10/916185
Inventors:
Muthiah Manoharan - Weston MA,
Venkitasamy Kesavan - Woburn MA,
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07H 21/04
A61K 31/70
US Classification:
536 245, 536 231, 514 44
Abstract:
The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e. g. , by using the non-ribose moiety as a point to which a ligand or other entity, e. g. , a lipophilic moiety. e. g. , cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.

Chemically Modified Oligonucleotides

View page
US Patent:
8017763, Sep 13, 2011
Filed:
Sep 17, 2009
Appl. No.:
12/561529
Inventors:
Muthiah Manoharan - Weston MA,
Venkitasamy Kesavan - Woburn MA,
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07H 21/04
A61K 31/70
US Classification:
536 245, 514 44
Abstract:
This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.

Ligand-Conjugated Monomers

View page
US Patent:
8404862, Mar 26, 2013
Filed:
Jul 2, 2009
Appl. No.:
12/497262
Inventors:
Muthiah Manoharan - Weston MA,
Venkitasamy Kesavan - Woburn MA,
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07F 9/06
US Classification:
548413
Abstract:
This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.

Single-Stranded And Double-Stranded Oligonucleotides Comprising A 2-Arylpropyl Moiety

View page
US Patent:
8470988, Jun 25, 2013
Filed:
Oct 23, 2009
Appl. No.:
12/604897
Inventors:
Muthiah Manoharan - Weston MA,
Venkitasamy Kesavan - Woburn MA,
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07H 21/02
C07H 21/04
US Classification:
536 231, 536 221
Abstract:
The present invention provides single-stranded and double-stranded oligonucleotides comprising at least one aralkyl ligand that improvise the pharmacokinetic properties of the oligonucleotide. The aralkyl ligands of the present invention include naproxen, ibuprofen, and derivatives thereof. The present invention also provides method for modulating gene expression using the modified oligonucleotide compounds and compositions comprising those modified oligonucleotides.

Modified Irna Agents

View page
US Patent:
8507661, Aug 13, 2013
Filed:
Feb 26, 2010
Appl. No.:
12/714298
Inventors:
Muthiah Manoharan - Weston MA,
Venkitasamy Kesavan - Woburn MA,
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07H 15/00
C07H 17/00
C07H 17/02
US Classification:
536 173, 536 41, 536 172, 536 187
Abstract:
The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e. g. , by using the non-ribose moiety as a point to which a ligand or other entity, e. g. , a lipophilic moiety. e. g. , cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.
Venkitasamy Kesavan from Highland Park, NJ, age ~50 Get Report